Linagliptin Eg (Linagliptin)

Linagliptin blocks the dipeptidyl peptidase‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, linagliptin enhances glucose‑dependent insulin release and reduces glucagon secretion, leading to lower blood glucose levels after meals.

The specific dose of Linagliptin Eg is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety data for linagliptin in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, linagliptin has a lower intrinsic risk of hypoglycaemia because it enhances insulin secretion only when glucose levels are elevated. Unlike metformin, it does not affect gastrointestinal absorption and can be used without dose adjustment in mild to moderate renal impairment.

Linagliptin Eg should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture, heat and light. Keep the product out of reach of children and do not use it after the expiry date.

Linagliptin Eg is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious risks include pancreatitis, severe allergic reactions such as anaphylaxis, and rare hepatic injury. Patients should seek immediate medical attention if they experience persistent severe abdominal pain, rash, swelling of the face or tongue, or signs of liver dysfunction.

Linagliptin Eg is contraindicated in patients with a known hypersensitivity to linagliptin or any component of the formulation. Caution is also advised for individuals with a history of pancreatitis, severe hepatic disease, or those taking other DPP‑4 inhibitors.